Dow Jones
38.466,32 +226,34 (+0,59%) Nasdaq
15.669,73 +218,43 (+1,41%) Nikkei 225
37.552,16 +113,55 (+0,30%) EUR/USD
1,0704 +0,0048 (+0,45%) Bitcoin EUR
62.319,66 +300,70 (+0,48%) CMC Crypto 200
1.436,35 +21,59 (+1,53%)
Vivoryon Therapeutics N.V. (0R3M.L)
| Chiusura precedente | 0,5700 |
| Aperto | 0,6300 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,6120 - 0,8300 |
| Intervallo di 52 settimane | 0,5000 - 19,4000 |
| Volume | |
| Media Volume | 3.012 |
| Capitalizzazione | 94.025 |
| Beta (5 anni mensile) | 1,27 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,6330 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireVivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference Participation
Vivoryon Therapeutics N.V. Announces Virtual R&D Event withKey Opinion Leaders and Upcoming Conference Participation Halle (Saale) / Munich, Germany, October 5, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced its plans to host a Virtual R&D Event with Key Opinion Leaders (KOLs
- GlobeNewswire
Vivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the Board
Vivoryon Therapeutics N.V. Extraordinary General MeetingApproved Appointment of New Executive Directors to the Board Halle (Saale) / Munich, Germany, September 15, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon, or the Company), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, held its Extraordinary General Meeting (EGM) today at 1:00 p.m. (
- GlobeNewswire
Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress
Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress Both VIVIAD and VIVA-MIND studies on track; final data from VIVIAD expected in Q1/2024, and a study update on VIVA-MIND expected in Q4/2023Varoglutamstat demonstrates very encouraging safety data with no drug-related ARIAs at therapeutic dose of 600 mg twice daily, a dose demonstrated to result in nearly 90% target occupancyDSMB meeting results support current protocol for VIVIAD and VIVA-MIND studie
